C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 116 filers reported holding C4 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $107,683 | +112.8% | 57,894 | +214.6% | 0.00% | – |
| Q2 2023 | $50,606 | +1035.7% | 18,402 | +1196.8% | 0.00% | – |
| Q1 2023 | $4,456 | -99.0% | 1,419 | -98.2% | 0.00% | – |
| Q4 2022 | $464,961 | -49.1% | 78,807 | -24.3% | 0.00% | -100.0% |
| Q3 2022 | $913,000 | +2436.1% | 104,083 | +2115.5% | 0.00% | – |
| Q2 2022 | $36,000 | -93.8% | 4,698 | -80.3% | 0.00% | – |
| Q1 2022 | $578,000 | -78.2% | 23,818 | -71.1% | 0.00% | -100.0% |
| Q4 2021 | $2,656,000 | -11.0% | 82,476 | +23.5% | 0.00% | -50.0% |
| Q3 2021 | $2,983,000 | +4.4% | 66,764 | -11.6% | 0.00% | 0.0% |
| Q2 2021 | $2,857,000 | +34.1% | 75,492 | +31.1% | 0.00% | +100.0% |
| Q1 2021 | $2,131,000 | +3080.6% | 57,604 | +2751.7% | 0.00% | – |
| Q4 2020 | $67,000 | – | 2,020 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |